Evidence map›Paper›PMID 28261167›Full record

ArticleFrontiers in microbiology2017

Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases.

Anja Hoffmann, Martina Richter, Susanne von Grafenstein, Elisabeth Walther, Zhongli Xu, Lilia Schumann, Ulrike Grienke, Christina E Mair, Christian Kramer, Judith M Rollinger and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Pyrrolo[2,3-RSC advances · 2023
    Article
  3. Sialidase Inhibitors with Different Mechanisms.Journal of medicinal chemistry · 2022
    Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Anja HoffmannDepartment of Virology and Antiviral Therapy, Jena University Hospital Jena, Germany.
Martina RichterDepartment of Virology and Antiviral Therapy, Jena University Hospital Jena, Germany.
Susanne von GrafensteinCentre for Chemistry and Biomedicine, Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck Innsbruck, Austria.
Elisabeth WaltherDepartment of Virology and Antiviral Therapy, Jena University Hospital Jena, Germany.
Zhongli XuDepartment of Virology and Antiviral Therapy, Jena University Hospital Jena, Germany.
Lilia SchumannDepartment of Virology and Antiviral Therapy, Jena University Hospital Jena, Germany.
Ulrike GrienkeDepartment of Pharmacognosy, Faculty of Life Sciences, University of Vienna Vienna, Austria.
Christina E MairDepartment of Pharmacognosy, Faculty of Life Sciences, University of Vienna Vienna, Austria.
Christian KramerCentre for Chemistry and Biomedicine, Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck Innsbruck, Austria.
Judith M RollingerDepartment of Pharmacognosy, Faculty of Life Sciences, University of Vienna Vienna, Austria.
Klaus R LiedlCentre for Chemistry and Biomedicine, Institute of General, Inorganic and Theoretical Chemistry, University of Innsbruck Innsbruck, Austria.
Michaela SchmidtkeDepartment of Virology and Antiviral Therapy, Jena University Hospital Jena, Germany.
Johannes KirchmairCentre for Chemistry and Biomedicine, Institute of General, Inorganic and Theoretical Chemistry, University of InnsbruckInnsbruck, Austria; Center for Bioinformatics, University of HamburgHamburg, Germany.
Jena University Hospital · DEUniversität Innsbruck · ATUniversity of Vienna · ATUniversität Hamburg · DE

Funding

Austrian Science Fund FWF P 23051Austrian Science Fund FWF P 24587
6 · The paper itself

Abstract

Viral neuraminidases are an established drug target to combat influenza. Severe complications observed in influenza patients are primarily caused by secondary infections with e.g.,

Indexed as

coinfectiondiazenylaryl sulfonic acidinfluenza virusneuraminidasesmall molecule inhibitorStreptococcus pneumoniae

Identifiers

PMID28261167
PMCPMC5309245
OpenAlexW2586045626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.